Inhibition of ERBB receptors can lead to suppression of cancer cell migration (Momeny et al., 2017) and inhibition of NRG1/ERBB2 signaling reduces migration of human glioma cells (Ritch et al., 2003). This evidence concerns the gene ERBB2 and central nervous system cancer.